Modalis Therapeutics Corporation (JP:4883)
:4883
Top Page
Modalis Therapeutics Corporation
(4883)
Select Model
Select Model
Rating:41Neutral
Price Target:
¥56.00
▲(0.00% Upside)
Action:ReiteratedDate:02/18/26
The score is held down primarily by very weak financial performance (minimal revenue, recurring losses, and sustained cash burn with equity erosion). Technicals also reflect a soft trend and negative momentum, while valuation signals are constrained by negative earnings and no dividend support in the provided data.
Positive Factors
Conservative balance sheet leverage
Reported zero total debt in 2024–2025 provides a durable financial cushion versus leveraged peers. Low leverage reduces fixed interest burdens, preserves optionality for R&D financing, and lowers near-term default risk, supporting runway while programs mature.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow indicates ongoing funding dependence. Over the coming months this elevates liquidity and dilution risk, constrains discretionary R&D investment pacing, and reduces resilience to capital-market stress.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet leverage
Reported zero total debt in 2024–2025 provides a durable financial cushion versus leveraged peers. Low leverage reduces fixed interest burdens, preserves optionality for R&D financing, and lowers near-term default risk, supporting runway while programs mature.
Read all positive factors
Modalis Therapeutics Corporation (4883) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.08B
Dividend YieldN/A
Average Volume (3M)719.68K
Price to Earnings (P/E)―
Beta (1Y)0.18
Revenue GrowthN/A
EPS Growth47.43%
CountryJP
Employees14
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-3.95
Shares Outstanding92,354,095
10 Day Avg. Volume617,120
30 Day Avg. Volume719,680
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.2
Revenue Forecast (FY)¥800.00M
Modalis Therapeutics Corporation Business Overview & Revenue Model
Company Description
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to...
How the Company Makes Money
Modalis Therapeutics Corporation generates revenue through a combination of strategic partnerships, research collaborations, and licensing agreements. The company partners with pharmaceutical and biotechnology firms to co-develop gene therapies, s...
Modalis Therapeutics Corporation Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
54
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 40.50M | 1.10M |
| Gross Profit | -583.00K | 0.00 | 0.00 | -731.00K | -83.17M | 1.10M |
| EBITDA | -2.33B | -2.21B | -2.15B | -2.37B | -2.58B | -667.55M |
| Net Income | -1.56B | -2.15B | -1.32B | -2.39B | -2.70B | -738.96M |
Balance Sheet | ||||||
| Total Assets | 3.42B | 2.96B | 3.69B | 2.03B | 3.13B | 6.07B |
| Cash, Cash Equivalents and Short-Term Investments | 3.26B | 2.81B | 3.58B | 1.88B | 2.93B | 4.94B |
| Total Debt | 0.00 | 0.00 | 0.00 | 412.50M | 0.00 | 0.00 |
| Total Liabilities | 228.82M | 170.94M | 143.47M | 645.50M | 188.60M | 519.92M |
| Stockholders Equity | 3.19B | 2.79B | 3.55B | 1.38B | 2.94B | 5.55B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.12B | -1.43B | -2.29B | -2.09B | -854.58M |
| Operating Cash Flow | 0.00 | -2.12B | -1.43B | -2.25B | -1.90B | -747.47M |
| Investing Cash Flow | 0.00 | -2.57M | -188.00K | -39.70M | -185.72M | 171.56M |
| Financing Cash Flow | 0.00 | 1.35B | 3.04B | 1.22B | 63.68M | 72.63M |
Modalis Therapeutics Corporation Technical Analysis
Negative
56.00
Price Trends
58.00
Negative
60.11
Negative
72.31
Negative
Market Momentum
-0.53
Positive
43.31
Neutral
18.10
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4883, the sentiment is Negative. The current price of 56 is below the 20-day moving average (MA) of 57.50, below the 50-day MA of 58.00, and below the 200-day MA of 72.31, indicating a bearish trend. The MACD of -0.53 indicates Positive momentum. The RSI at 43.31 is Neutral, neither overbought nor oversold. The STOCH value of 18.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4883.
Modalis Therapeutics Corporation Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥15.07B | 16.22 | ― | ― | -5.41% | ― | |
64 Neutral | ¥6.22B | 11.64 | ― | 3.21% | 4.25% | ― | |
53 Neutral | ¥9.55B | -7.86 | -90.96% | ― | 243.16% | -23.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥6.16B | -6.80 | ― | ― | 56.17% | -11.63% | |
43 Neutral | ¥6.42B | -0.95 | ― | ― | -50.27% | -3.33% | |
41 Neutral | ¥5.08B | -3.55 | ― | ― | ― | 47.43% |
* Healthcare Sector Average
JP:4883
Modalis Therapeutics Corporation
55.00
-21.00
-27.63%
JP:4597
Solasia Pharma KK
34.00
2.00
6.25%
JP:4539
Nippon Chemiphar Co., Ltd.
1,725.00
317.98
22.60%
JP:4574
Taiko Pharmaceutical Co., Ltd.
297.00
36.00
13.79%
JP:4582
Symbio Pharmaceuticals Limited
102.00
-42.00
-29.17%
JP:4892
Cyfuse Biomedical K.K.
612.00
-377.00
-38.12%
Modalis Therapeutics Corporation Corporate Events
Modalis Slows IND Timeline for Lead CRISPR Program as It Strengthens Clinical Readiness
Feb 12, 2026
Modalis Therapeutics reported continued progress in preparing its lead candidate MDL-101 for clinical trials, citing consistent survival benefits in disease model mice and no new safety concerns, while conducting further analyses to refine develop...
Modalis Loss Widens on Higher R&D Spend Amid Zero Revenue in FY2025
Feb 12, 2026
Modalis Therapeutics has reported a widening loss for the fiscal year ended December 31, 2025, with consolidated operating income falling to a deficit of ¥2,211 million and profit attributable to owners of the parent deepening to a loss of &#...
Modalis Books Foreign Exchange Gain for FY2025 on Currency Revaluation
Feb 12, 2026
Modalis Therapeutics Corporation reported non-operating income of ¥10 million in foreign exchange gains for the fiscal year ended December 31, 2025, driven mainly by the revaluation of its foreign currency-denominated assets and liabilities a...
Modalis Issues FY2025 Report With Strict Confidentiality and Risk Disclaimers
Feb 12, 2026
Modalis Therapeutics Corporation released an English reference version of its business and financial report for the fiscal year ending in 2025, dated February 12, 2026, clarifying that the Japanese version remains the authoritative document. The c...
Modalis posts wider losses in 2025, with no revenue and no 2026 guidance
Feb 12, 2026
Modalis Therapeutics reported no operating revenue for the fiscal year ended December 31, 2025, and widened its consolidated loss, with operating income at a loss of ¥2,211 million and profit attributable to owners of parent at a loss of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.